7.00
0.00%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Interpace Biosciences
From its filings with the US Securities and Exchange Commission
Interpace Biosciences is based in Parsippany, New Jersey and is incorporated in Delaware. Its shares trade on OTC under the ticker IDXG. The SEC classifies its business as surgical & medical instruments & apparatus. In the fiscal year to 31 December 2025, it reported revenue of $38.7m and net income of $24.6m. At that date it held total assets of $33.8m and shareholders' equity of $22.4m.
Clinical services that help guide patient management decisions by providing information on the diagnosis and prognosis of indeterminate specimens. Guidance on genetic marker-related pharmaceutical treatment options, when available, is also provided.
Establishing payer relationships and in-network contracts serving our diagnostic customers.
Expanding understanding and utilization of our bioinformatics data to improve our assays and elevate scientific understanding of the genetic drivers of cancer progression and aggressiveness.
(CAP) and our products are approved by New York State. We are leveraging our laboratory to refine and commercialize our assays and products.
CLIA inspectors may make random inspections of clinical laboratories outside of the renewal process.
We believe that we have structured our business operations and relationships with our customers to comply with applicable legal requirements.
However, it is possible that governmental entities or other third parties could interpret these laws differently and assert otherwise.
We discuss below the statutes and regulations that are most relevant to our business and most frequently cited in enforcement actions.
Quoted from its 10-K, filed 30 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Health Care Providers & Services
- Listed since
- 19 May 1998
- Employees
- 94
- Website
- interpace.com ↗
- Head office
- WATERVIEW PLAZA, SUITE 310, PARSIPPANY, NJ, 07054
- Incorporated in
- DE
- Classification
- Surgical & Medical Instruments & Apparatus
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Dr. Thomas BurnellExecutive Chairman, President, Chief Executive Officer, since 2020$657,730
- Mr. Christopher MccarthyChief Financial Officer$434,533
- Dr. Vijay AggarwalIndependent Director$50,000
- Dr. Joseph KeeganIndependent Director$100,000
- Mr. Fortunato RoccaIndependent Director$40,000
- Mr. Stephen SullivanIndependent Director, since 2004$100,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Interpace Diagnostics offers five commercialized molecular tests for cancer risk evaluation.
- PancraGEN and PanDNA provide pancreatic cancer diagnosis from cysts using advanced technology.
- ThyGeNEXT and ThyraMIR v2 enable thyroid cancer diagnosis from nodules with sequencing assays.
Weaknesses
- The company employs only 94 full-time employees, limiting operational capacity.
- Interpace Biosciences has no tests in clinical evaluation beyond PanDNA's program.
- Parsippany, New Jersey headquarters may restrict regional market access.
Opportunities
- Expanding molecular test applications in pancreatic cancer diagnosis with PancraGEN.
- Increasing adoption of ThyGeNEXT for thyroid cancer diagnosis in clinical settings.
- RespriDX differentiates lung cancer origins, offering new market potential.
Threats
- Competition from other Health Care sector diagnostics companies in the US market.
- Regulatory changes affecting molecular diagnostic test approvals in the US.
- Limited employee count may hinder rapid response to market demands.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.